Business Wire

Ian Read named Chairman of the Board of Areteia Therapeutics

Share

Areteia Therapeutics, Inc. (“Areteia”) today announced that its Board of Directors has appointed Ian Read as Chairman of the Board. Mr. Read’s appointment as Areteia’s first Chairman follows the launch of the Company by Knopp Biosciences and Population Health Partners and the successful completion of the Company’s $350 million Series A financing led by Bain Capital Life Sciences, with participation from Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, and Population Health Partners.

“I am excited that Ian has been appointed as Chairman,” said Jorge Bartolome, Chief Executive Officer of Areteia. “He is an incredibly esteemed executive whose depth of experience, proven leadership and expert judgment will be invaluable to me and the Board of Directors as we focus on delivering on the Company’s strategy and advancing the Phase III program for dexpramipexole, the first potential oral drug for eosinophilic asthma.”

Commenting on his appointment, Mr. Read said, “I am honored to be chosen to serve as Chairman of Areteia and look forward to working with Jorge and the team. This is a compelling opportunity to address a high unmet need for severe asthmatics by bringing a new oral medicine to market to potentially treat eosinophilic asthma earlier in the treatment paradigm and offer patients and health systems an alternative to injectable biologics.”

Mr. Read brings to his role a distinguished 42-year track record as one of the foremost leaders, dealmakers, and value creators in the global biopharmaceutical industry. He was Chairman and Chief Executive Officer of Pfizer, Inc. from December 2010 until January 2019, and Executive Chairman until December 2019. During that tenure, he oversaw over 30 new drug approvals, $88 billion in acquisition and divestiture deals, and a total shareholder return of 250%—representing over $242 billion in value creation. Mr. Read oversaw a period of industry-shaping innovation regarding the structure of Pfizer and its portfolio, including novel spin-outs and acquisitions alongside dozens of major licensing agreements. Mr. Read currently serves as a partner of Population Health Partners.

About Areteia Therapeutics

Areteia Therapeutics, Inc. (areteiatx.com) is a clinical stage biotechnology company committed to putting asthma patients in better control of their disease and lives by developing the first potential oral drug for eosinophilic asthma. Areteia’s lead drug candidate is dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences. A syndicate of leading life sciences and strategic investors led by Bain Capital Life Sciences with participation from Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, and Population Health Partners, has committed to invest up to $350 million in Series A financing to establish Areteia and advance dexpramipexole through Phase III clinical trials, secure commercial supply, and pursue potential next-generation medicines. Areteia will conduct late-stage development, including Phase III clinical trials of dexpramipexole, in partnership with Population Health Partners’ development unit, Validae Health.

About Dexpramipexole

Dexpramipexole is an oral small molecule in Phase III development for eosinophilic asthma. Dexpramipexole inhibits the maturation and release of eosinophils in bone marrow, based on evidence from cell cultures and human biopsies, thereby lowering peripheral blood eosinophil levels. Most recently in a Phase II study in patients with moderate-to-severe eosinophilic asthma, treatment with dexpramipexole resulted in a significant, dose-dependent reduction in blood absolute eosinophil count at all doses tested (daily dexpramipexole doses of 37.5 mg, 75 mg, or 150 mg twice daily) compared to placebo. Dexpramipexole was well tolerated in the trial, with adverse events balanced across treatment and placebo groups, no serious adverse events, and no adverse events leading to discontinuation.

About Eosinophilic Asthma

Asthma disrupts the lives of more than a quarter of a billion people worldwide. More than half of asthma patients have eosinophilic asthma, which is driven by an oversupply of eosinophils, a type of white blood cell, in blood and tissue. By inhibiting the maturation of eosinophils, oral dexpramipexole acts in a way similar to injectable anti-IL-5 biologic therapies. The asthma biologic market is experiencing growth of 10% per year and is valued at around $8 billion, with IL-5 biologic therapies representing approximately $3 billion of that figure. If approved as a first-to-market oral, dexpramipexole could provide a compelling alternative to injectable biologics, and could potentially be used earlier in the asthma treatment paradigm to prevent progression of disease.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Tamsin Berry
Tamsin.Berry@areteiatx.com

Mark Kreston
Mark.Kreston@areteiatx.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Adrestia appoints Will Lewis as Chair, establishes US Operations and appoints new functional leads29.9.2022 13:00:00 CEST | Press release

Adrestia Therapeutics, a leader in synthetic rescue therapies for genetic diseases, today announced that it appointed William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors, Jennifer Millian, M.S., M.B.A. as VP of U.S. Operations, and Philip Coxon, Ph.D., as VP of Business Development. This extends Adrestia’s presence to the United States and deepens its drug development capabilities as it moves its emerging pipeline of first-in-class therapeutics towards the clinic. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220928005044/en/ Will Lewis, Adrestia Chairman “Adrestia’s leading synthetic rescue platform is systematically mining the human genome to find new ways of treating patients with currently intractable diseases” said Lewis. “The team unites world-class biology and drug discovery leadership with an exciting vision for genetic medicine. We are discovering new biology that opens fresh ways of thinking about ta

Fluor Selected for Expansion of Large-Scale Biologics Manufacturing Facility in Scandinavia29.9.2022 12:54:00 CEST | Press release

Fluor Corporation (NYSE: FLR) announced today that the company has been selected by a leading biologics company to perform procurement and construction management for a large-scale biologics drug substance manufacturing facility located in Scandinavia. Fluor will book the multi-hundred-million-dollar reimbursable contract value in the third quarter of 2022. The facility will produce new capacity for advanced biologics that are used in a variety of treatments including vaccines, oncology and quality-of-life medicines. Fluor has performed the planning and enabling work for this project, and construction is now underway with the facility scheduled to be operational by 2025. Fluor’s Advanced Technologies & Life Sciences business is leading the project including support from its Nordic Technology Hub in Copenhagen, Denmark. About Fluor Corporation Fluor Corporation (NYSE: FLR) is building a better future by applying world-class expertise to solve its clients’ greatest challenges. Fluor’s 41

Versace Chooses Board to Transform Retail Planning29.9.2022 12:22:00 CEST | Press release

Board, the leading global provider of Intelligent Planning Solutions which help organizations plan smarter — enabling actionable insights and better outcomes, today announced that Versace, the Italian fashion house that symbolizes luxury worldwide, has chosen Board to transform its Retail Planning. The Versace Group distributes its products through a direct network of over 200 owned boutiques and 1,500 distributors worldwide, with a turnover of more than one billion euros. Due to evolving challenges of global sourcing and the change in consumer purchasing habits, Versace recently revamped its retail strategy by opening new stores, strengthening their multi-channel approach and increasing investments in the efficiency of crucial business planning processes. "Board’s Intelligent Planning platform, provides the flexible and easy to use solutions necessary to support the innovation and growth of our brand,” said Francesco Loporcaro, IT Manager at Versace “Our selection of Board was influen

Satellogic Signs Three-Year Agreement with Government of Albania to Access Dedicated Satellite Constellation29.9.2022 12:00:00 CEST | Press release

Satellogic Inc. (NASDAQ: SATL), a leader in sub-meter resolution Earth Observation (“EO”) data collection, announced today that it has reached a three-year agreement with the Government of Albania to develop a Dedicated Satellite Constellation. This unique program derives from Satellogic’s Constellation-as-a-Service model and will provide Albania with responsive satellite imagery capabilities across its sovereign territory. Satellogic’s unique offering enables municipal, state, and national governments to manage a fleet of satellites over a specific area of interest and develop an EO imaging program at unmatched frequency, resolution, and cost. Satellogic will enable ​​Albania to address pressing issues involving agriculture management, illegal crops, illegal construction activity, traffic management, wildfire monitoring, border security, and environmental monitoring through high-quality imagery with country-wide capacity at a cost-effective price point. Albania will have priority acce

Burjeel Holdings Lights Up Burj Khalifa With New Campaign Featuring Shah Rukh Khan29.9.2022 11:27:00 CEST | Press release

A month ahead of his birthday, Indian actor Shah Rukh Khan lit up the world’s tallest building, The Burj Khalifa, on Wednesday evening, in a brand campaign for the UAE-based conglomerate Burjeel Holdings. For the past few years, on Shah Rukh Khan’s birthday, the Burj Khalifa has lit up in honor of the superstar. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220929005378/en/ The brand campaign of Burjeel Holdings featuring Shah Rukh Khan premiering at Burj Khalifa on Wednesday evening (Photo: AETOSWire) Shah Rukh Khan is the face of the group that owns 39 hospitals and medical centers under the Burjeel, Medeor, LLH, Lifecare, and Tajmeel brands in the UAE and Oman. The campaign, ‘We Are Committed To Your Care’, which is set to appear region-wide on multiple platforms features the Abu Dhabi-headquartered healthcare powerhouse’s homegrown success story. It is based on the group’s vision of connecting care, scale & community in